New hope for breast cancer: experimental combo enters human trials

NCT ID NCT07358377

Recruiting now Disease control Sponsor: Atridia Pty Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug called HRS-6209 combined with standard hormone therapies (fulvestrant or letrozole) in people with a certain type of advanced breast cancer (HR-positive/HER2-negative). The main goal is to check safety and find the right dose. About 15 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Ballarat Base Hospital
RECRUITING

Ballarat, Victoria, Australia
Frankston Hospital
RECRUITING

Frankston, Victoria, Australia
GenesisCare Frenchs Forest
RECRUITING

Sydney, New South Wales, 2086, Australia
GenesisCare St Leonards
RECRUITING

Sydney, New South Wales, 2068, Australia
Lyell McEwin Hospital
RECRUITING

Elizabeth Vale, South Australia, Australia
Southern Highlands Private Hospital
RECRUITING

Bowral, New South Wales, 2567, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.